USE OF TETRAACETYLATED 5-AMINO-4-CARBAMOYL IMIDAZOLYL-1-β-D-RIBOFURANOSIDE AS A PROTEIN KINASE Cδ INHIBITOR Russian patent published in 2020 - IPC A61K31/7056 C07H17/02 C07D405/04 A61P43/00 

FIELD: chemistry.

SUBSTANCE: invention refers to organic chemistry and medicine. Disclosed is use of a tetraacetyled derivative of 5-amino-4-carbamoylimidazolyl-1-β-D-ribofuranoside – ((AcO)₄AICAR) as a selective inhibitor of protein kinase Cδ. (AcO)₄AICAR effectively inhibits protein kinase Cδ (PKCδ) due to specific inhibition of PKCδ/NF-κB signaling pathway.

EFFECT: because (AcO)₄AICAR does not possess high toxicity with respect to healthy cells, it allows using it in disturbances prevention of PKCδ/NF-κB signaling pathway, for example to prevent apoptosis or increased thrombosis.

4 cl, 4 dwg, 6 ex